Safety and effectiveness of selective retina therapy (SRT) for central serous chorioretinopathy

Safety and effectiveness of selective retina therapy (SRT) for central serous chorioretinopathy - Safety and effectiveness of SRT for CSCR

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005396

Enrollment

Registered

2011-05-01

Start date

2011-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

central serous chorioretinopathy

Interventions

methods: After local anesthesia with Benoxil ophthalmic solution, we irradiate SRT laser for the lesion. periodical evaluation: Three months after first therapy, we retreat if the treatment is in

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with central serous chorioretinopathy caused subjective symptoms such as central scotoma, metamorphopsia and central visual loss

Exclusion criteria

Exclusion criteria: ophthalmic exclusion criteria: patients who had inflammation within the eye systemic exclusion criteria: people who had systemic inflammatory disease, hemorrhagic diathesis or anticoagulant therapy, untreated hypertension or diabetes mellitus. peple who is pregnant or at risk of becoming pregnant.

Design outcomes

Primary

Measure	Time frame
observation of optic coherence tomography	—

Countries

Japan

Contacts

Public ContactManabu Yamamoto

Osaka City University, Graduate School of Medicine, Department of Ophthalmology and Visual sciences Ophthalmology

manabun@msic.med.osaka-cu.ac.jp06-6645-3867

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026